Ironwood Pharmaceuticals INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Ironwood Pharmaceuticals, Inc. has issued its proxy statement detailing the agenda for its 2026 Annual Meeting of Stockholders, including director elections, executive compensation votes, and equity plan amendments.
NASDAQ
Ironwood Pharmaceuticals has scheduled its 2025 Annual Meeting for June 10, 2025, outlining key proposals for stockholder voting, including the election of directors and executive compensation.
NASDAQ
Ironwood Pharmaceuticals will hold its 2025 annual meeting of stockholders virtually on June 10, 2025, to vote on director elections, executive compensation, and auditor ratification.
NASDAQ
DEFA14A: Ironwood Pharmaceuticals Sets Date for 2024 Annual Meeting, Outlines Proposals for Stockholder Vote
Ironwood Pharmaceuticals has scheduled its annual stockholder meeting for June 18, 2024, where stockholders will vote on the election of directors, executive compensation, and the ratification of the company's independent auditor.
NASDAQ
Ironwood Pharmaceuticals' proxy statement details the agenda for the 2024 annual meeting of stockholders and highlights the company's progress in maximizing LINZESS, advancing its GI pipeline, and delivering sustained profits and cash flows.